This pharmacoepidemiology study uses national Canadian electronic medical record data to describe treatment indications for antidepressants and temporal trends in antidepressant prescribing for depression in Quebec, Canada, from 2006 through 2015.
This randomized clinical trial assesses whether combination naltrexone-bupropion treatment in overweight and obese patients increases major adverse cardiovascular events (MACE) compared with placebo.
This meta-analysis summarizes published evidence about the prevalence of mental health conditions in patients undergoing bariatric surgery and associations between those conditions and weight loss outcomes.
This Viewpoint discusses the potential use of combined naltrexone extended-release plus bupropion extended-release for adjunctive treatment of obesity.
Kushner and Ryan review current best practices for assessment and lifestyle management of obesity and describe how updated guidelines can be applied to individual patients.
Ebberts and colleagues compare the efficacy and safety of varenicline and sustained-release bupropion vs varenicline alone in 506 adult cigarette smokers in a randomized, blinded, placebo-controlled, 12-week clinical trial (52-week follow-up) at 3 centers from October 2009 through April 2013.